2X-111 is under clinical development by Smerud Medical Research International and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how 2X-111’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
2X-111 overview
2B3-101 (glutathione pegylated liposomal doxorubicin) is under development for the treatment of recurrent malignant glioma, HER2 positive metastatic breast cancer and brain metastases from breast cancer. The drug candidate is administered through intravenous route. It is a formulation of doxorubicin glutathione-PEG liposome. Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. It intercalates between base pairs in the DNA helix and targets DNA synthesis. The drug candidate is developed based on G-Technology platform which is a pegylated (PEG) liposomal drug delivery system. It was also under development for the treatment of leptomeningeal disease (neoplastic meningitis, leptomeningeal carcinomatosis).
Smerud Medical Research International overview
Smerud Medical Research International (Smerud Medical) is a contract research organization that offers drug development services. The company conducts clinical trials to pharmaceutical and biotechnology companies for improving new medical compounds. It provides services such as clinical trial management, project funding, consulting, data management and training services. Smerud Medical provides clinical trial management such as planning of clinical development programmes, feasibility studies and closing of trial centres, among others. The company provides project funding services such as research grants, and project strategy. It also provides consulting services such as clinical development programmes, regulatory strategy and ethics, among others. The company operates through its offices located in Sweden, Denmark, Norway, Finland, Poland, Russia and the UK. Smerud Medical is headquartered in Oslo, Norway.
For a complete picture of 2X-111’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
